News Agency
Men's Weekly

Inmagene Doses First Patient in Phase 2a Trial of IMG-007, an Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Alopecia Areata

  • Written by PR Newswire
  • IMG-007 is a novel anti-OX40 monoclonal antibody (mAb) engineered for potentially once every 12 weeks dosing and an improved safety profile
  • IMG-007 is being evaluated for the treatment of alopecia areata (AA) and atopic dermatitis (AD)
  • An interim data readout in AA is expected in Q3 2024

SAN DIEGO, Oct. 13, 2023 /PRNewswire/ -- Inmagene...

Read more: Inmagene Doses First Patient in Phase 2a Trial of IMG-007, an Anti-OX40 Monoclonal Antibody with...

Defense Industry Jobs and Defence Recruitment: Building Careers That Shape National Security

The defence sector is one of the most important contributors to national security, innovation, and economic growth. Across Australia and worldwide, defense industry jobs offer opportunities for individuals to work in fields that combine technology, strategy, and service to the nation... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion